Jack Jones

Cooley advised GeBBS Healthcare Solutions, a global provider of healthcare outsourcing solutions, and ChrysCapital, a top India-focused private equity firm, on the agreement for BPEA Private Equity Fund VIII (EQT Private Capital Asia) to acquire a controlling beneficial interest in GeBBS from ChrysCapital.

Cooley advised ChrysCapital, a top India-focused private equity firm, on the close of its oversubscribed $700 million continuation fund and general partner-led secondary transaction to purchase and sell its stake in the National Stock Exchange of India (NSE) with two of the world’s leading secondary fund investors. The landmark transaction is the largest of its kind in India and ranks among the largest in the Asia-Pacific region.

Cooley advised Autolus – a clinical-stage biopharmaceutical company developing next-generation programmed T-cell therapies – on its strategic collaboration with BioNTech, an immunotherapy company pioneering novel therapies for cancer and other serious diseases, to advance both companies’ autologous CAR-T programs toward commercialization, as well as a $350 million underwritten offering.

Cooley advised Amryt Pharma, a Dublin, Ireland-based commercial-stage biopharmaceutical company, on its definitive agreement to be acquired by Chiesi Farmaceutici, a Parma, Italy-based research-focused biopharmaceuticals and healthcare group, in a $1.48 billion cash and contingent value right (CVR) transaction. Partners Bill Sorabella, Claire Keast-Butler and Bill Roegge led the joint US and UK Cooley team advising Amryt.

Cooley advised 2C2P, a global payments platform, on its strategic partnership with Ant Group, an innovative technology provider that strives to bring the world inclusive, green and sustainable services. Lawyers Matthew Bartus and Gwenlynne Lee led the Cooley team advising 2C2P.